Sarah Gilbert is a distinguished English vaccinologist renowned for her pivotal contributions to vaccine development, particularly in response to emerging viral pathogens. As a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech, she has dedicated her career to advancing public health through innovative vaccine research. Her early work focused on host-parasite interactions in malaria, which laid the groundwork for her later achievements in vaccine design.
In 2010, Gilbert became a Professor at the Jenner Institute, where she spearheaded the development of novel influenza vaccines. Her groundbreaking research led to the creation of a universal flu vaccine that stimulates T cell responses rather than relying solely on antibody production. This innovative approach has the potential to provide long-lasting immunity and reduce the need for annual vaccinations, particularly benefiting the elderly population.
Gilbert’s most notable achievement came during the COVID-19 pandemic when she led the rapid development of the Oxford-AstraZeneca vaccine. Within weeks of identifying the new virus, her team designed a vaccine that was subsequently approved for use in the UK by December 2020. This vaccine has since been distributed globally, with over 3 billion doses supplied, showcasing her ability to respond effectively to urgent public health needs.
Throughout her career, Gilbert has received numerous accolades for her contributions to science, including the Rosalind Franklin Medal and being named a Dame Commander of the Order of the British Empire. Her work continues to inspire future generations of scientists and public health professionals, solidifying her legacy as a leader in vaccinology.